Mineralys Therapeutics (MLYS) CMO sells 2,171 shares after option exercise

Rhea-AI Filing Summary

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman exercised stock options for 2,171 shares of common stock at $16.00 per share and on the same day sold 2,171 shares at $26.84 per share in an open-market transaction. The filing describes these moves as an exercise or conversion of derivative securities followed by a sale. After the transactions, he directly owned 82,489 shares of common stock and held stock options covering 23,876 shares. The company notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025, indicating they were scheduled in advance.

Insider Trade Summary 10b5-1

Net Seller: 2,171 shares ($58,270)

Net Sell 3 txns

Insider Rodman David Malcom

Role Chief Medical Officer

Sold 2,171 shs ($58K)

Type	Security	Shares	Price	Value
Exercise	Stock Option	2,171	$0.00	--
Exercise	Common Stock	2,171	$16.00	$35K
Sale	Common Stock	2,171	$26.84	$58K

Holdings After Transaction: Stock Option — 23,876 shares (Direct); Common Stock — 84,660 shares (Direct)

Footnotes (1)

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodman David Malcom

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		M(1)		2,171	A	$16	84,660	D
Common Stock	03/09/2026		S(1)		2,171	D	$26.84	82,489	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$16	03/09/2026		M(1)			2,171	(2)	02/09/2033	Common Stock	2,171	$0	23,876	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

2. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Mineralys Therapeutics (MLYS) report for its CMO?

Mineralys Therapeutics reported that its Chief Medical Officer exercised options for 2,171 shares at $16.00 and sold 2,171 common shares at $26.84. These transactions occurred on March 9, 2026 as an exercise of derivative securities followed by an open-market sale.

How many Mineralys Therapeutics (MLYS) shares does the CMO hold after this Form 4?

After the reported transactions, the Chief Medical Officer directly owned 82,489 shares of Mineralys Therapeutics common stock. The Form 4 also shows stock options covering 23,876 shares remained outstanding following the option exercise reported in the filing.

At what prices did the Mineralys Therapeutics (MLYS) CMO exercise and sell shares?

The Chief Medical Officer exercised stock options at $16.00 per share to acquire 2,171 Mineralys Therapeutics shares, then sold 2,171 common shares at $26.84 per share. The exercise converted derivative securities into common stock before the open-market sale.

Was the Mineralys Therapeutics (MLYS) CMO’s share sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan adopted on October 6, 2025. Such plans schedule trades in advance, indicating these transactions followed a pre-arranged program rather than ad hoc market timing.

What type of derivative security did the Mineralys Therapeutics (MLYS) CMO exercise?

The filing shows the Chief Medical Officer exercised a stock option, a derivative security granting the right to buy shares, to acquire 2,171 shares of common stock at $16.00 per share. Following this exercise, stock options for 23,876 shares remained outstanding.